C‐reactive protein/albumin ratio is a poor prognostic factor of esophagogastric junction and upper gastric cancer. Issue 2 (6th September 2018)

• Record Type: Journal Article
• Authors: Kudou, Kensuke; Saeki, Hiroshi; Nakashima, Yuichiro; Kamori, Tomohiro; Kawazoe, Tetsuro; Haruta, Yasuhiro; Fujimoto, Yoshiaki; Matsuoka, Hiroya; Sasaki, Shun; Jogo, Tomoko; Hirose, Kosuke; Hu, Qingjiang; Tsuda, Yasuo; Kimura, Koichi; Ando, Koji; Oki, Eiji; Ikeda, Tetsuo; Maehara, Yoshihiko
• Is Part Of: Journal of gastroenterology and hepatology. Volume 34:Issue 2(2019)
• Page Start: 355
• Page End: 363
• Publication Date: 2018-09-06
• Subjects: adenocarcinoma of esophagogastric junction -- C‐reactive protein/albumin ratio -- gastric cancer; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Liver Diseases -- Periodicals; 616.33
• DOI: 10.1111/jgh.14442
• Languages: English
• ISSNs: 0815-9319

Abstract

Abstract: Background and Aim: The C‐reactive protein (CRP)/albumin (Alb) ratio has been reported as a novel prognostic marker in several cancers. The objective of this study was to investigate the prognostic value of the CRP/Alb ratio in patients who underwent surgery for adenocarcinoma of the esophagogastric junction (AEG) and upper gastric cancer (UGC). Methods: Data for 144 patients who underwent surgery for AEG and UGC were reviewed. The CRP/Alb ratio, neutrophil–lymphocyte ratio, platelet–lymphocyte ratio, Glasgow Prognostic Score, and controlling nutritional status score were calculated, and the relationship between these biomarkers and postoperative prognosis was analyzed. Results: The optimal cutoff value of the CRP/Alb ratio was determined to be 0.1. According to the cutoff value of CRP/Alb ratio, patients were divided into two groups (CRP/Alb < 0.1, n = 124; CRP/Alb ≥ 0.1, n = 20). The 5‐year recurrence‐free survival and overall survival (OS) rates were significantly lower in the patients with the CRP/Alb ratio ≥ 0.1 than in those with the CRP/Alb ratio < 0.1 (recurrence‐free survival: 44.9% vs 77.9%, P = 0.0011; OS: 43.4% vs 82.0%, P < 0.0001). In the multivariate analyses, the N‐stage, and CRP/Alb ratio ≥ 0.1 were identified as independent predictive factors for OS in patients with AEG and UGC ( P = 0.0061 and P = 0.0439, respectively). Conclusions: The CRP/Alb ratio was strongly associated with poor prognosis in patients who underwent surgery for AEG and UGC.